公司表示，在2025年世界肺癌大会发表的一期研究数据近期显示，针对曾接受免疫治疗的晚期鳞状非小 细胞肺癌(SQ-NSCLC)的17例可评估患者，IMM2510的客观缓解率及疾病控制率分别达到35.3%及 76.5%，中位缓解持续时间为7.59个月，中位无进展生存期为9.4个月。基于上述结果，公司计划透过三 期临床试验进一步验证IMM2510的疗效与安全性，旨在为肺癌患者提供更有效的治疗选择。 智通财经APP获悉，宜明昂科-B(01541)再涨超9%，截至发稿，涨7.94%，报15.77港元，成交额2182.88 万港元。 消息面上，宜明昂科近日公布，日前已向国家药品监督管理局药品审评中心，提交IMM2510用于治疗 经免疫治疗耐药性非小细胞肺癌(NSCLC)的三期临床试验的申请，并于近期递交两项针对不同类型肺癌 的三期注册临床试验。 （原标题：港股异动 | 宜明昂科-B(01541)再涨超9% 公司近日提交IMM2510三期临床试验申请） ...

Core Viewpoint - The announcement highlights the acceptance of the key Phase II registration clinical trial results for TY-9591, a novel EGFR-TKI, at the 2025 World Lung Cancer Conference, indicating significant progress in the treatment of EGFR mutation-positive NSCLC with brain metastases [1] Company Summary - Company has developed TY-9591, a new generation EGFR-TKI, aimed at treating EGFR mutation-positive non-small cell lung cancer (NSCLC) [1] - The clinical trial results will be presented by Professor Shi Yuankai from the Beijing Cancer Hospital, showcasing the drug's efficacy in controlling brain metastases and alleviating symptoms [1] - Company acknowledges uncertainty regarding the successful development, commercialization, and market launch of TY-9591 [1] Industry Summary - The acceptance of the trial results at a prestigious international conference underscores the potential of new treatments in the oncology sector, particularly for challenging cases like NSCLC with brain metastases [1] - The development of targeted therapies like TY-9591 reflects ongoing innovation in the pharmaceutical industry aimed at improving patient outcomes in cancer treatment [1]